Noninvasive ventilation (NIV) as an adjunct strategy for increasing exercise tolerance has been widely investigated in patients with pulmonary diseases. To our knowledge, there are no studies that have used NIV during exercise in patients with decompensated heart failure (HF). The aim of this study was to evaluate the effects of NIV on exercise tolerance in hospitalized patients with decompensated HF. Thirteen patients (77 ± 15 years) with a mean left ventricular ejection fraction of 35 ± 15% were included. Patients underwent 2 submaximal exercise tests with constant load for lower limbs using a portable cycle ergometer. Tests were performed on the same day with a 60-minute interval between each one, using a randomized crossover design: sham ventilation (continuous positive airway pressure mode, 4 cm HO) and intervention situation (NIV in bilevel mode). Primary outcome was the endurance time performed during exercise tests with constant load. Submaximal exercise with NIV in bilevel mode improved endurance time (7.2 ± 2.7 minutes) compared to the tests performed with continuous positive airway pressure (5.1 ± 1.5 minutes; p = 0.008). Increase in endurance time (Δ time) with bilevel test showed a significant correlation with reduction in the slope of dyspnea (Δ Borg) over time (r = -0.73; p = 0.004). There was a significant correlation between endurance time in bilevel tests and maximum inspiratory pressure % predicted (r = 0.68; p = 0.02). In conclusion, NIV was effective in increasing exercise tolerance in hospitalized patients with decompensated HF. (ClinicalTrials.gov registration NCT02122848).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2016.10.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review.
Curr Oncol Rep
January 2025
Department of Radiology, Albert Einstein College of Medicine and the Montefiore Medical Center, 111 East 210Th Street, Bronx, NY, 10461, USA.
Purpose Of Review: This paper reviewed the current literature on incidence, clinical manifestations, and risk factors of Chimeric Antigen Receptor T-cell (CAR-T) cardiotoxicity.
Recent Findings: CAR-T therapy has emerged as a groundbreaking treatment for hematological malignancies since FDA approval in 2017. CAR-T therapy is however associated with a few side effects, among which cardiotoxicity is of significant concern.
[Rehabilitation after intercurrent morbid event of patients suffering from neurocognitive disorders in a pilot unit: management and outcomes].
Geriatr Psychol Neuropsychiatr Vieil
December 2024
Pôle recherche LNA Santé, Vertou, France.
People suffering from a neurodegenerative disease, at a stage still allowing physical activity, encounter more difficulties to access to re-education and rehabilitation care. A trial unit specialized in medical care and rehabilitation (SMR) was created to handle these patients, who suffered a morbid intercurrent event not related to the neurocognitive disorder. The trial unit was created thanks to a dedicated funding from the Brittany Health Regional Agency (ARS) following-up a call for projects in October 2021.
View Article and Find Full Text PDFSensitivity of Lung Point-of-Care Ultrasound (POCUS) to Predict Oxygen Requirements in Emerging Viral Infections.
J Ultrasound Med
January 2025
Department of Emergency Medicine, The University of Arizona College of Medicine, Tucson, Arizona, USA.
Objectives: The prognostic characteristics of lung point-of-care ultrasound (L-POCUS) to predict respiratory decompensation in patients with emerging infections remains unstudied. Our objective was to examine whether scored lung ultrasounds predict hypoxia among a nonhypoxic, ambulatory population of patients with COVID-19.
Methods: This was a diagnostic case-control study.
Aims: Risk prediction indices used in worsening heart failure (HF) vary in complexity, performance, and the type of datasets in which they were validated. We compared the performance of seven risk prediction indices in a contemporary cohort of patients hospitalized for HF.
Methods And Results: We assessed the performance of the Length of stay and number of Emergency department visits in the prior 6 months (LE), Length of stay, number of Emergency department visits in the prior 6 months, and admission N-Terminal prohormone of brain natriuretic peptide (NT-proBNP (LENT), Length of stay, Acuity, Charlson co-morbidity index, and number of Emergency department visits in the prior 6 months (LACE), Get With The Guidelines Heart Failure (GWTG), Readmission Risk Score (RRS), Enhanced Feedback for Effective Cardiac Treatment model (EFFECT), and Acute Decompensated Heart Failure National Registry (ADHERE) risk indices among consecutive patients hospitalized for HF and discharged alive from January 2017 to December 2019 in a network of hospitals in England.
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors.
Pediatr Blood Cancer
January 2025
Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
Background: Immune effector cell (IEC) therapies, including chimeric antigen receptor (CAR)-modified T-cell therapy, have shown efficacy in pediatric B-cell acute lymphoblastic leukemia (B-ALL) and are being investigated for other malignancies. A common toxicity associated with IEC therapy is cytokine release syndrome (CRS), which can lead to cardiovascular decompensation due to systemic inflammation. Data are limited regarding cardiovascular adverse effects in children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!